Life Sciences Virtual Investor Conference: Company Executives Present Live March 10th Pharmaceutical Investing
Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer Pharmaceutical Investing
Merck's KEYTRUDA® Demonstrated Significant Improvement in Distant Metastasis-Free Survival Compared to Placebo as Adjuvant Therapy for Patients With Resected Stage IIB and IIC Melanoma in Phase 3 KEYNOTE-716 Trial Life Science Investing
Merck to Hold Investor Event to Highlight Growing Cardiovascular Portfolio and Pipeline Life Science Investing
U.S. Food and Drug Administration Approves Opdivo® with Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients with Resectable Non-Small Cell Lung Cancer Pharmaceutical Investing
Medtronic continuous glucose monitoring to be reimbursed for eligible people living with type 1 diabetes in Ontario Medical Device Investing
Love Pharma Updates Microdoz Proposed Acquisition with Global Leader in Psychedelic Research Pharmaceutical Investing
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
